Jeffrey Cummings, M.D. (UCLA)

Dr. Cummings is the Augustus S. Rose Professor of Neurology and is also Professor of Psychiatry and Biobehavioral Sciences at UCLA. Dr. Cummings is Founder and Director of the UCLA Alzheimer’s Disease Center. The Center has an active clinical trials program and fosters imaging, genetics, clinical and neuroscience research. Dr. Cummings is Director of the UCLA Behavioral Neuroscience and Dementia Research Fellowship. Many of the approximately 40 fellows that he has trained currently hold leadership positions in dementia programs throughout the United States and the world. He is the Founder and Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. Dr. Cummings’ interests embrace clinical trials and the development of new treatments for neurodegenerative disorders and other neurological diseases. He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association and in 2005 was named Edward Henderson State-of-the-Art Lecturer by the American Geriatrics Society. Dr. Cummings has authored or edited 20 books and over 450 peer reviewed papers. He has broad interests in dementing disorders, neuropsychiatry, neurotherapeutics, and the interface of neuroscience and society.

Stephen Freedman, Ph.D. (Elan, Merck)

Dr. Freedman is the founder and owner of SBF Consulting LLC, a drug hunting support organization, working with the biotech industry to bring new therapeutics into the clinic.  Dr. Freedman has almost 25 years experience in the industry and his background includes senior positions at Merck and Co. and was most recently Sr Vice President, Head of Global Research for Elan Pharmaceuticals.  He has interests in a number of therapeutic areas including neurology, psychiatry, pain, inflammation and a number of associated autoimmune diseases including asthma, RA and IBD.

Hans Mikkelsen, Ph.D. (Roche, Parke-Davis, Pfizer)

Dr. Mikkelsen is a consultant in clinical development and specializes in psychiatry and neurology. Dr. Mikkelsen has almost 25 years experience in the pharmaceutical industry. His background includes senior positions at Roche, Parke-Davis and Pfizer, most recently Site Head for Pfizer/Parke-Davis’ International Clinical Development Group in France. His primary interest is the clinical development of new therapies in psychiatry and neurology.

Christopher  F. O’Brien, M.D. (Neurocrine Biosciences, Inc, San Diego)

Dr. O’Brien is Sr. Vice President Clinical Development at Neurocrine Biosciences and Associate Professor (Voluntary), Department of Neuroscience,University of California San Diego. He has been active as an Investigator in clinical research in neurodegenerative disorders (e.g., Huntington’s Disease, Parkinson’s Disease) within Academic and Industry settings for more than 15 years. His primary interest is the clinical development of new therapies for unmet medical needs.

James G. Ottinger, R.Ph. (SCIREX Corporation, Horsham, Pennsylvania)

James Ottinger is Senior Vice President of Regulatory Affairs at SCIREX Corporation and is responsible for regulatory strategy and operations, medical writing, and quality assurance.  SCIREX is a Clinical Research Organization with specific expertise in drug development in the areas of neurological and psychiatric disorders, and pain and inflammation.  Mr. Ottinger has over 20 years of regulatory experience from both SCIREX and Wyeth Research, where he was responsible for global regulatory programs in Alzheimer’s disease, anxiety disorders, bipolar disorders, major depression, multiple sclerosis, neuropathic pain, schizophrenia and stroke.

Leslie Patmore, Ph.D. (Syntex, Quintiles, Aptuit)

Dr. Leslie Patmore is currently Managing Director of Aptuit Consulting Inc., the consulting division of Aptuit, a global drug development services company. Areas of consulting include drug development strategy, execution and safety assessment with particular expertise in QT prolongation. Until October 2005, Dr. Patmore was Vice President of the Preclinical Sciences and Pharmaceutical Analysis operations at Quintiles’ European pharmaceutical development centre in Edinburgh and worked for Quintiles for 10 years in various management positions. Dr Patmore has a B.Sc. and Ph.D. in Physiology and Biophysics and over 25 years of experience in pharmaceutical research and development. Previously at Syntex Pharmaceuticals for 15 years and with Roche briefly following the acquisition of Syntex in 1995, he has held positions in discovery research, safety assessment and as a leader of drug development programs. Actively involved in basic science and pharmaceutical R&D scientific societies, Dr. Patmore is a regular speaker at international opinion forming conferences and has particular interests in targets for new therapeutic entities and safety of drugs relating to proarrhythmic risk. Dr. Patmore holds an Honorary Research Fellowship in the Department of Medicine at Edinburgh University and serves as a Board Director of the Safety Pharmacology Society.

Peter Jeffrey Snyder, Ph.D. (University of Connecticut, Pfizer)

Dr. Snyder received his doctorate in clinical psychology and behavioral neuroscience, from Michigan State University in 1992, following an internship in clinical neuropsychology at the Long Island Jewish Medical Center (New York, USA).  Dr. Snyder received a Wilder Penfield Research Fellowship in 1992 from the Epilepsy Foundation of America, and he served as a Clinical Neurosciences Fellow in the NIMH Clinical Research Center for the Study of Schizophrenia at Hillside Hospital (Albert Einstein College of Medicine) in 1992 and 1993.   He serves as an Associate Editor of Brain and Cognition, and he has delivered over 100 presentations at international scientific conferences. From 1998 to 2005, Dr. Snyder was employed as a scientist, clinician and manager at Pfizer Global Research & Development – Groton Laboratories (Connecticut, USA) – the largest research laboratory of Pfizer, Inc.  Dr. Snyder was responsible for the identification and development of novel clinical technologies for the CNS therapeutic area at Pfizer.  Then, as a Director and Early Clinical Leader, Dr. Snyder led the early clinical development of novel compounds for the treatment of schizophrenia and Alzheimer’s disease at Pfizer, Inc.  Dr. Snyder left Pfizer in late 2005, to return to academia as a Professor (with tenure) in the Department of Psychology at the University ofConnecticut (Storrs, CT).  Dr. Snyder teaches graduate courses in cognitive neuroscience and clinical neuropsychology, he maintains an active laboratory, and he serves as the major professor for several graduate and post-doctoral students.  Dr. Snyder consults to several private corporations, and he is an active adjunct faculty member in the Yale Child Study Center, Yale University School of Medicine.

Thomas Thompson, Ph.D. (Quintiles, Hoechst Marion Roussell)

Dr. Thompson is the head of R&D Services, a pharmaceutical consulting firm specializing in preclinical and early clinical development.  He has 24 years experience in the pharmaceutical industry in the fields of preclinical and clinical ADME, pharmacokinetics and drug metabolism, and has worked in the Pharma, CRO and consulting sectors.  Dr. Thompson has published and presented widely in the areas of animal and human ADME, pharmacokinetics, drug metabolism and drug interactions.

James White, Ph.D. (Hypnion)